Bioreactors are manufacturing devices or vessels in which biological reactions are performed and are used to grow various organisms, such as yeast, bacteria, or animal cells, in an appropriate environment. According to Marketstack, the Global Bioreactors Market is expected to grow considerably during the forecasted period. Factors such as the growth of bioreactors in pharmaceuticals and the adoption of single-use bioreactors (SUBs) and hybrid bioreactors are expected to drive the bioreactors market in the forecasted period. Further, the technological advancements in bioreactors have improved the flexibility, quality, and scalability of operations with low capital and energy requirements. They are expected to drive the bioreactors market in the forecasted period. Furthermore, the surging prevalence of chronic diseases such as cancer, cardiovascular disease, and diabetes would fuel the development of therapeutics and are expected to drive the bioreactors market in the forecasted period. However, a lack of availability and access to various alternative bioreactor methods and a stringent regulatory environment for the system and materials used are expected to restrain the bioreactors market in the forecasted period.

The increased usage of single-use bioreactors by biopharmaceutical companies and research institutions drives market growth. Moreover, the increasing demand for monoclonal antibodies and biosimilars and the rising usage of single-use bioreactors for mammalian cell culture in several research studies are the driving features of the bioreactors market growth. Single-use bioreactors, also called disposable bioreactors, use disposable bags rather than stainless steel or glass culture vessels. Single-use bioreactors have a broad range of uses in academic & industrial laboratories, including pharmaceutical, drug discovery, environmental, and life science research for producing vaccines, cell culture, antibodies, and biofuels, among other things. These factors also help boost market growth. However, single-use bioreactors (SUBs) reduce labour costs, minimize the risk of cross-contamination, and eliminate cleaning process and verification issues. The various bioreactors are planned as round & hollow designs and come in multiple sizes and limits with varying materials like carbon steel, glass bioreactors, artistic bioreactors, Polytetrafluoroethylene (PTFE) plastic, and tempered steel bioreactors. Small-scale systems have traditionally been utilized for preliminary research, such as screening many experimental conditions. Single-use bioreactors use disposable bags instead of reusable steel vessels operated in conventional bioreactors. Small-scale bioreactors (less than 100 mL working volume) require fewer cells, are more economical, and need less labour than larger bioreactors. Using small-scale bioreactors permits high-throughput experimentation to test operating & growth conditions (media components, agitation rate, cell density) and the resulting interactions. Small-scale bioreactors shorten the turnaround time by saving time on assembly, sanitization, and autoclaving processes. A scalable, small-scale suspension bioreactor system would need fewer cells & less labour than was previously possible with larger suspension bioreactors. The range of stainless-steel bioreactors and associated high capital costs have become challenging due to the changing demand for biopharmaceuticals. SUBs' versatility in meeting the rising demand for biopharmaceuticals has enabled them to address the issues related to traditional bioreactors successfully. The flexibility offered by single-use bioreactors is one of the main encouraging factors for investing in technology that further drives the single-use bioreactors market growth.

North America currently dominates a significant share of the market for bioreactors, and it is expected to continue its stronghold for a few more years. This region is predicted to increase its market share, owing to the rise in collaboration among the industry and academic institutions. The United States holds most of the market in the North American region because pharmaceuticals and hi-tech product makers have announced multimillion-dollar investments to expand manufacturing capabilities. The automated bioreactor segment can be specialised equipment for cultivating microorganisms, mammalian cells, and other biological entities. In addition, the increasing demand for automated bioreactors is driven by several factors, primarily in biotechnology, pharmaceuticals, and industrial microbiology.

Moreover, the biopharmaceutical industry relies heavily on bioreactors to produce therapeutic proteins, monoclonal antibodies, vaccines, and other biologics. In addition, automated bioreactors can ensure consistent and controlled production processes, leading to higher product yields and improved product quality. The global bioreactor market is majorly propelled by the elevating prevalence of various chronic diseases, such as diabetes and cancer, especially amongst the steadily surging geriatric population.

Additionally, significant technological advancements, such as introducing single-use bioreactors (SUBs) for optimizing the flexibility, quality, and scalability of microorganisms' formation operations with minimising cost and energy requirements, positively stimulate market growth. Rising biopharmaceutical manufacturing capacities across developing nations and the increasing demand for bioreactors that evolve, have high cell density, and support modern and intensified clinical processes demanding high oxygen transfer and significant carbon dioxide (CO2) removal are propelling the market growth. Technological development is also expected to play an instrumental role in using advanced bioreactors and various equipment of a progressive nature. Cultivation parameters can be observed through the help of screens, and all of these advanced characteristics will lead to the market's growth. Quality data can be collected through the usage of such developments, and it also leads to less human intervention. The rapid expansion in the pharmaceutical and biologics sectors, the demanding need for effective treatment drugs, and the surging awareness among consumers regarding the formulation and availability of personalized medicines contribute significantly to the market growth.

The market's key players are Sartorius AG, Thermo Fisher Scientific Inc., General Electric, Eppendorf AG, and Merck KGaA.

In 2022, Merck announced the acquisition of Lonza's MAST platform, an automated aseptic bioreactor sampling system. These platforms assist customers in optimizing data during bioprocessing. This acquisition will help the company in expanding its market presence.

In March 2023, MarqMetrix introduced its latest 'Single-use BioReactor BallProbe.' Increasing acceptance of disposable technologies in the biopharmaceutical business served as the impetus for developing this new product. The company understood the need for solutions to lessen the danger of contamination while increasing productivity and lowering expenses.

Global Bioreactors Market report provides deep insight into the Industrial market's current and future state across various regions. The study comprehensively analyses the Bioreactors Market by segmenting based on Type (Glass, Stainless Steel, and Single-use), Usage (Lab-scale Production, Pilot-scale Production, and Full-scale Production), Scale (5L-20L, 20L-200L, 200L-1,500L, and Above 1,500L), Control (Manual and Automated), End User (Research and Development Departments, Biopharmaceutical Companies, Biopharmaceutical Manufacturer and CMOs)  and Geography (Asia-Pacific, North America, Europe, South America, and Middle East & Africa). The report examines the market drivers and restraints and the impact of COVID-19 on market growth in detail. The study covers emerging market trends, development, opportunities, and challenges in the industry. This report also covers extensively researched competitive landscape sections with prominent companies and profiles, including their market shares and projects.